Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR35 | Q9HC97 | 4/20 | 0.41 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.39 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.39 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.39 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.39 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.39 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.39 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.39 |
| ▸ | TTR | P02766 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | S100A4 | P26447 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16037644 | 0.87 | GPR35 (0.42) | GPR35GRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL18614418 | 0.85 | GRIN2D (0.39) | GPR35GRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL29833722 | 0.82 | GRIN2D (0.42) | GPR35GRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL2892253 | 0.82 | GRIN2D (0.42) | GPR35GRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL6141212 | 0.82 | MAPT (0.37) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL17744276 | 0.82 | ALDH1A1 (0.41) | GPR35GRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL26908210 | 0.82 | GRIN2D (0.45) | GPR35GRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL17219535 | 0.81 | MAPT (0.36) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL17744336 | 0.80 | GPR35 (0.38) | GPR35GRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL8161795 | 0.80 | GPR35 (0.47) | GPR35GRIN2DGRIN3BGRIN1GRIN2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12421217-B2 | Pyrazine derivative or salt thereof, and use of same | FUJIFILM CORPORATION (JP) | 2025-09-23 | — | — | US | disclosed |
| EP-4561561-A2 | SUBSTITUTED 3,4-DIHYDROQUINOLINONE INHIBITORS OF TSHR | Septerna, Inc. (US) | 2025-06-04 | — | — | EP | disclosed |
| EP-4052760-B1 | PYRAZINE DERIVATIVE OR SALT THEREOF, AND USE OF SAME | FUJIFILM CORP (JP) | 2024-03-13 | — | — | EP | disclosed |
| US-20240043420-A1 | 7-AZAINDOLE COMPOUNDS FOR INHIBITION OF BCR-ABL TYROSINE KINASES | ENLIVEN INC. | 2024-02-08 | — | — | US | disclosed |
| WO-2024026076-A2 | SUBSTITUTED 3,4-DIHYDROQUINOLINONE INHIBITORS OF TSHR | SEPTERNA, INC. (US) | 2024-02-01 | — | — | WO | disclosed |
| EP-4284785-A1 | DIAMINOTRIAZINE COMPOUNDS | BASF SE (DE) | 2023-12-06 | — | — | EP | disclosed |
| CN-116964037-A | Diaminotriazine compounds | 巴斯夫欧洲公司 | 2023-10-27 | — | — | CN | disclosed |
| EP-4225741-A1 | 7-AZAINDOLE COMPOUNDS FOR INHIBITION OF BCR-ABL TYROSINE KINASES | Enliven Therapeutics, Inc. (US) | 2023-08-16 | — | — | EP | disclosed |
| CN-116438182-A | 7-azaindole compounds for inhibiting BCR-ABL tyrosine kinase | 活力疗法公司 | 2023-07-14 | — | — | CN | disclosed |
| EP-4052760-A1 | PYRAZINE DERIVATIVE OR SALT THEREOF, AND USE OF SAME | FUJIFILM Corporation (JP) | 2022-09-07 | — | — | EP | disclosed |
| WO-2021085582-A1 | PYRAZINE DERIVATIVE OR SALT THEREOF, AND USE OF SAME | 富士フイルム株式会社 | 2021-05-06 | — | — | WO | disclosed |
| EP-3020718-B1 | NOVEL PDE4 INHIBITOR | MEIJI SEIKA PHARMA CO LTD (JP) | 2018-12-26 | — | — | EP | disclosed |
| US-9890142-B2 | PDE4 inhibitor | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2018-02-13 | — | — | US | disclosed |
| US-9850235-B2 | — | — | 2017-12-26 | — | — | US | disclosed |
| US-20160159783-A1 | PDE4 Inhibitor | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2016-06-09 | — | — | US | disclosed |
| EP-3020718-A1 | NOVEL PDE4 INHIBITOR | Meiji Seika Pharma Co., Ltd. (JP) | 2016-05-18 | — | — | EP | disclosed |
| US-8252820-B2 | 1-orthofluorophenyl substituted 1,2,5-thiazolidinedione derivatives as PTP-as inhibitors | NOVARTIS AG (CH) | 2012-08-28 | — | — | US | disclosed |
| US-20100035942-A1 | 1-orthofluorophenyl substituted 1,2,5-thiazolidinedione derivatives as ptp-as inhibitors | NOVARTIS AG (CH) | 2010-02-11 | — | — | US | disclosed |
| EP-1963293-A1 | 1-ORTHOFLUOROPHENYL SUBSTITUTED 1, 2 , 5-THIAZOLIDINEDIONE DERIVATIVES AS PTP-AS INHIBITORS | Novartis AG (CH) | 2008-09-03 | — | — | EP | disclosed |
| WO-2007067612-A1 | 1-ORTHOFLUOROPHENYL SUBSTITUTED 1, 2, 5-THIAZOLIDINEDIONE DERIVATIVES AS PTP-AS INHIBITORS | NOVARTIS AG (CH) | 2007-06-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240043420-A1 | 7-AZAINDOLE COMPOUNDS FOR INHIBITION OF BCR-ABL TYROSINE KINASES | ABL1, ABL2, BCR | GPR35 2360/4885GRIN2D 2692/4885GRIN3B 1487/4885 |
| US-12421217-B2 | Pyrazine derivative or salt thereof, and use of same | DHODH, IDH1, IDH2 | GPR35 3104/4885GRIN2D 3380/4885GRIN3B 4137/4885 |
| US-20160159783-A1 | PDE4 Inhibitor | PDE4A, PDE4B, PDE3B | GPR35 1891/4885GRIN2D 4503/4885GRIN3B 3892/4885 |
| US-20100035942-A1 | 1-orthofluorophenyl substituted 1,2,5-thiazolidinedione derivatives as ptp-as inhibitors | PTPRS, PTPRF, PTPRO | GPR35 761/4885GRIN2D 1837/4885GRIN3B 2465/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.